Pagibaximab

Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis[1].

Product Specifications

CAS Number

[595566-61-3]

Product Name Alternative

BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody

UNSPSC

12352203

Target

Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pagibaximab.html

Purity

98.81

Solubility

H2O

Smiles

[Pagibaximab]

Molecular Weight

(145.42 kDa)

References & Citations

[1]Weisman LE, et, al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011 Aug;128 (2) :271-9.